OBJECTIVE: Epidermal growth factor receptor inhibitors can result in a severe rash in 5-10% of patients and can detract from quality of life. The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials. METHODS:933 cetuximab-treated patients enrolled on N0147, an adjuvant chemotherapy trial for colon cancer, were evaluated for clinical risk factors of severe rash. RESULTS: Within this cohort, 50 patients (5%) developed a severe rash (grade 3). More men compared to women developed such a rash: 34 (7%) versus 16 (3%) (multivariate odds ratio = 2.12; 95% confidence interval: 1.14-3.88; p = 0.017). A greater number of younger patients (<70 years of age) also developed a rash: 48 (6%) versus 2 (1%) (multivariate odds ratio = 0.21; 95% confidence interval: 0.05-0.88; p = 0.032). Race and performance score were not predictive. CONCLUSION: Men and younger patients are at greater risk for a severe cetuximab-induced rash although overall the risk is low. These observations are particularly important in designing future rash prevention and palliation trials. Copyright 2009 S. Karger AG, Basel.
RCT Entities:
OBJECTIVE: Epidermal growth factor receptor inhibitors can result in a severe rash in 5-10% of patients and can detract from quality of life. The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials. METHODS: 933 cetuximab-treated patients enrolled on N0147, an adjuvant chemotherapy trial for colon cancer, were evaluated for clinical risk factors of severe rash. RESULTS: Within this cohort, 50 patients (5%) developed a severe rash (grade 3). More men compared to women developed such a rash: 34 (7%) versus 16 (3%) (multivariate odds ratio = 2.12; 95% confidence interval: 1.14-3.88; p = 0.017). A greater number of younger patients (<70 years of age) also developed a rash: 48 (6%) versus 2 (1%) (multivariate odds ratio = 0.21; 95% confidence interval: 0.05-0.88; p = 0.032). Race and performance score were not predictive. CONCLUSION:Men and younger patients are at greater risk for a severe cetuximab-induced rash although overall the risk is low. These observations are particularly important in designing future rash prevention and palliation trials. Copyright 2009 S. Karger AG, Basel.
Authors: F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont Journal: Eur J Cancer Date: 1999-09 Impact factor: 9.162
Authors: Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern Journal: J Clin Oncol Date: 2007-12-01 Impact factor: 44.544
Authors: Bret Wacker; Tina Nagrani; Jacqueline Weinberg; Karsten Witt; Gary Clark; Pablo J Cagnoni Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Bogdan Dascalu; Hagen F Kennecke; Howard J Lim; Daniel J Renouf; Jenny Y Ruan; Jennifer T Chang; Winson Y Cheung Journal: Support Care Cancer Date: 2015-07-17 Impact factor: 3.603